572 related articles for article (PubMed ID: 25099483)
1. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
3. Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2.
Xia Y; Zhang G; Kou L; Yin S; Han C; Hu J; Wan F; Sun Y; Wu J; Li Y; Huang J; Xiong N; Zhang Z; Wang T
Brain; 2021 Aug; 144(7):2024-2037. PubMed ID: 33792662
[TBL] [Abstract][Full Text] [Related]
4. Hippocampal proliferation is increased in presymptomatic Parkinson's disease and due to microglia.
Doorn KJ; Drukarch B; van Dam AM; Lucassen PJ
Neural Plast; 2014; 2014():959154. PubMed ID: 25197578
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
[TBL] [Abstract][Full Text] [Related]
6. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.
Desai Bradaric B; Patel A; Schneider JA; Carvey PM; Hendey B
J Neural Transm (Vienna); 2012 Jan; 119(1):59-71. PubMed ID: 21748523
[TBL] [Abstract][Full Text] [Related]
7. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
8. Neuroinflammation is associated with Alzheimer's disease co-pathology in dementia with Lewy bodies.
Wetering JV; Geut H; Bol JJ; Galis Y; Timmermans E; Twisk JWR; Hepp DH; Morella ML; Pihlstrom L; Lemstra AW; Rozemuller AJM; Jonkman LE; van de Berg WDJ
Acta Neuropathol Commun; 2024 May; 12(1):73. PubMed ID: 38715119
[TBL] [Abstract][Full Text] [Related]
9. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
10. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
11. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
12. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
[TBL] [Abstract][Full Text] [Related]
13. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.
Reynolds AD; Glanzer JG; Kadiu I; Ricardo-Dukelow M; Chaudhuri A; Ciborowski P; Cerny R; Gelman B; Thomas MP; Mosley RL; Gendelman HE
J Neurochem; 2008 Mar; 104(6):1504-25. PubMed ID: 18036154
[TBL] [Abstract][Full Text] [Related]
14. Role of cytokines in inflammatory process in Parkinson's disease.
Sawada M; Imamura K; Nagatsu T
J Neural Transm Suppl; 2006; (70):373-81. PubMed ID: 17017556
[TBL] [Abstract][Full Text] [Related]
15. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies.
Rozemuller AJ; Eikelenboom P; Theeuwes JW; Jansen Steur EN; de Vos RA
Acta Neuropathol; 2000 Dec; 100(6):701-8. PubMed ID: 11078223
[TBL] [Abstract][Full Text] [Related]
16. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
17. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?
Frigerio R; Fujishiro H; Ahn TB; Josephs KA; Maraganore DM; DelleDonne A; Parisi JE; Klos KJ; Boeve BF; Dickson DW; Ahlskog JE
Neurobiol Aging; 2011 May; 32(5):857-63. PubMed ID: 19560232
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
19. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.
Milber JM; Noorigian JV; Morley JF; Petrovitch H; White L; Ross GW; Duda JE
Neurology; 2012 Dec; 79(24):2307-14. PubMed ID: 23152586
[TBL] [Abstract][Full Text] [Related]
20. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders.
Patterson L; Rushton SP; Attems J; Thomas AJ; Morris CM
Brain Pathol; 2019 Jul; 29(4):544-557. PubMed ID: 30582885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
